MiMedx Group, Inc. (NASDAQ:MDXG) Position Lessened by Isthmus Partners LLC

Isthmus Partners LLC reduced its stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 22.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 306,413 shares of the company’s stock after selling 86,801 shares during the period. Isthmus Partners LLC owned 0.21% of MiMedx Group worth $1,811,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Paradigm Capital Management Inc. NY raised its holdings in MiMedx Group by 6.6% during the second quarter. Paradigm Capital Management Inc. NY now owns 4,167,200 shares of the company’s stock valued at $28,879,000 after buying an additional 258,700 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in MiMedx Group by 6.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,435,397 shares of the company’s stock valued at $8,483,000 after buying an additional 92,726 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in MiMedx Group by 47.0% during the second quarter. Dimensional Fund Advisors LP now owns 1,292,822 shares of the company’s stock valued at $8,958,000 after buying an additional 413,443 shares in the last quarter. Harbor Capital Advisors Inc. raised its holdings in MiMedx Group by 299.9% during the third quarter. Harbor Capital Advisors Inc. now owns 1,027,738 shares of the company’s stock valued at $6,074,000 after buying an additional 770,744 shares in the last quarter. Finally, Royce & Associates LP raised its holdings in MiMedx Group by 5.3% during the third quarter. Royce & Associates LP now owns 972,853 shares of the company’s stock valued at $5,750,000 after buying an additional 48,539 shares in the last quarter. 79.15% of the stock is currently owned by institutional investors.

MiMedx Group Trading Up 2.2 %

Shares of MDXG opened at $9.43 on Friday. MiMedx Group, Inc. has a 12-month low of $5.47 and a 12-month high of $9.64. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $1.39 billion, a price-to-earnings ratio of 17.15 and a beta of 1.94. The stock’s 50-day moving average price is $6.79 and its 200 day moving average price is $6.88.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on MDXG. Craig Hallum cut their target price on MiMedx Group from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, August 1st. Cantor Fitzgerald reissued an “overweight” rating and set a $11.00 price objective on shares of MiMedx Group in a research report on Thursday, August 1st. Finally, StockNews.com cut MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 8th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, MiMedx Group has a consensus rating of “Buy” and a consensus target price of $12.00.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.